At ELRIG Drug Discovery (9 ‒10 October 2018; London, UK) we spoke to Ola Engkvist, section head in the Hit Discovery Department at AstraZeneca (Cambridge, UK). In this interview, he explains the benefits of using artificial intelligence in the drug discovery process and the changes he believes it will bring to medicinal chemistry on the whole.